PubReading [89] - Immunotherapy and prevention of pancreatic cancer - A. Morrison, K. Byrne and R. Vonderheide

<p><strong>Pancreatic cancer</strong> is the third leading cause of cancer mortality in the United States, recently surpassing breast cancer. A key component of pancreatic cancer’s lethality is its acquired immune privilege, which is driven by an immunosuppressive microenvironment, poor T-cell infiltration, and a low mutational burden. Although <strong>immunotherapies</strong> such as checkpoint blockade or engineered T cells have yet to demonstrate efficacy, a growing body of evidence suggests that orthogonal combinations of these and other strategies could unlock immunotherapy in pancreatic cancer. In this review, we will discuss promising immunotherapies currently under investigation in pancreatic cancer and provide a roadmap for the development of <strong>prevention</strong> vaccines for this and other cancers. - doi:10.1016/j.trecan.2018.04.001 - 2018</p>